Ipsen S.A. (OTCMKTS:IPSEY – Get Free Report)’s share price crossed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $29.07 and traded as high as $30.27. Ipsen shares last traded at $30.27, with a volume of 494 shares traded.
Ipsen Stock Performance
The stock’s 50-day simple moving average is $28.85 and its 200 day simple moving average is $29.07.
Ipsen Company Profile
Ipsen SA operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. Its product pipeline comprises Cabometyx + Atezolizumab, which is in phase III clinical trial for the treatment of second line metastatic castration-resistant prostate cancer; lenalidomide and rituximab, and Taverik, which is in phase III for the treatment of second line follicular lymphoma; Bylvay, which is in phase III for the treatment of biliary atresia; Dysport, which is in phase III clinical trial for the treatment of chronic and episodic migraine; Fidrisertib, which is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressiva; Elafibranor, which is in phase II for the treatment of primary sclerosing cholangitis, as well as IPN60250; IPN10200, which is in phase II for the treatment of longer-acting neurotoxin aesthetics and therapeutics; IPN60210, which is in phase I clinical trial for the treatment of relapsed/refractory multiple myeloma; and IPN60260 for the treatment of Viral cholestatic disease and is in phase I clinical trial.
Recommended Stories
- Five stocks we like better than Ipsen
- How to invest in blue chip stocks
- It’s Time to Buy Into the Super Micro Computer Stock Implosion
- How Investors Can Find the Best Cheap Dividend Stocks
- Merger or Not, Albertson’s Companies is a Good Buy
- What is the Australian Securities Exchange (ASX)
- 3 Cheap Stocks That Shouldn’t Be So
Receive News & Ratings for Ipsen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ipsen and related companies with MarketBeat.com's FREE daily email newsletter.